Can FLT3 inhibitors overcome resistance in AML?

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 13-20

  Tam, Winnie F ^a   Gary Gilliland, D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AML; CEP701; FLT3 inhibitors; lestaurtinib; midostaurin; MLN 518; PKC412; resistance; staurosporine; SU11248; tandutinib

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 PROTEIN INHIBITOR; IMATINIB; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; PLACEBO; PROTEIN KINASE C INHIBITOR; SU 1148; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RESISTANCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; IC 50; LEUKEMIA REMISSION; LEUKEMOGENESIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; POINT MUTATION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARBAZOLES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; MUTATION; PIPERAZINES; QUINAZOLINES; STAUROSPORINE;

EID: 40849085718     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.003     Document Type: Review

References (24)

1. Kelly L.M., Liu Q., Kutok J.L., et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99 (2002) 310-318
2. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
3. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
4. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. The Journal of the American Medical Association 295 (2006) 2516-2524
5. Motzer R.J., Hoosen S., Bello C.L., et al. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opinion on Investigational Drugs 15 (2006) 553-561
6. Fabbro D., Ruetz S., Bodis S., et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Design 15 (2000) 17-28
7. Levis M., Allebach J., Tse K.F., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 (2002) 3885-3891
8. Kelly L.M., Yu J.C., Boulton C.L., et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1 (2002) 421-432
9. DeAngelo D.J., Amrein P.C., Kovacsocics T.J., et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 108 (2006) 51a [abstract 158]
10. De Angelo D.J., Stone R., Heaney M.L., et al. Phase II ealuation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation. Blood 104 (2004) 496a [abstract 1792]
11. Stone R.M., De A.J., Galinsky I., et al. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Annals of Hematology 83 Suppl. 1 (2004) S89-S90
12. Knapper S., Burnett A.K., Littlewood T., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (2006) 3262-3270
13. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 (2002) 433-443
14. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
15. Stone R.M., Fischer T., Paquette R., et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood 108 (2006) 50a [abstract 157]
16. Levis M., Smith D., Beran M., et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood 106 (2005) 121a [abstract 403]
17. Levis M., Brown P., Smith B.D., et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108 (2006) 3477-3483
18. Nakano Y., Kiyoi H., Miyawaki S., et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. British Journal of Haematology 104 (1999) 659-664
19. Shih L.Y., Huang C.F., Wu J.H., et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 100 (2002) 2387-2392
20. Cloos J., Goemans B.F., Hess C.J., et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20 (2006) 1217-1220
21. Clark J.J., Cools J., Curley D.P., et al. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 104 (2004) 2867-2872
22. Cools J., Mentens N., Furet P., et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Research 64 (2004) 6385-6389
23. Heidel F., Solem F.K., Breitenbuecher F., et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107 (2006) 293-300
24. Levis M., Pham R., Smith B.D., et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104 (2004) 1145-1150